A French IVD group with €168 million in 2025 revenues just paid €145 million (roughly $170 million) to acquire a division that generated $48 million in product sales last year, a multiple that signals strategic urgency rather than financial opportunism. Eurobio Scientific closed its purchase of CareDx’s transplant Lab Products division on July 1, folding CareDx AB in Sweden and its U.S. and Australian subsidiaries into GenDx, Eurobio’s Netherlands-based HLA typing affiliate. The deal closed ahead of schedule, which matters here: the integration clock starts earlier than the market priced in.
The strategic logic centers on workflow completeness, not just revenue addition. GenDx has built a strong position in NGS-based HLA typing, but CareDx’s Lab Products brought a complementary suite of real-time PCR kits, hybrid capture technology, and post-transplant monitoring reagents. The combined portfolio now spans the full transplantation diagnostic cycle, from pre-transplant HLA matching through post-transplant surveillance. That end-to-end coverage is increasingly what clinical and research labs are willing to pay a premium for, particularly as the HLA typing for transplant market is projected to grow from roughly $770 million in 2026 to $1.09 billion by 2031. Capturing share in a compounding market is a different business than defending a static one.
What makes the price defensible is geographic leverage. GenDx already had distribution reach across Europe and a footprint in San Diego for U.S. customers; the CareDx assets add established commercial relationships in the United States and Asia-Pacific that would have taken years to build organically. CareDx’s Lab Products revenue grew from $40.8 million in 2024 to $48 million in 2025, a nearly 18% increase, so Eurobio is acquiring a business with demonstrable momentum, not a distressed carve-out. For Eurobio, whose proprietary product sales grew 20% in 2025 and now represent 35% of total revenue, folding in a 100% proprietary portfolio from CareDx directly accelerates that mix shift toward higher-margin, owned IP.
The number to track now is the proprietary product revenue share in Eurobio’s H1 2026 results, due July 28. If the CareDx assets are already moving that ratio meaningfully above 35%, it will confirm that the integration is accretive faster than the deal price implies, and reprice expectations for the full year accordingly.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
